Nektar Therapeutics rallies after releasing new 52-week alopecia areata data for rezpegaldesleukin

Nektar Therapeutics (NKTR) is up 18.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to Nektar’s release of new 52-week topline results from a blinded 16-week treatment extension in its Phase 2b REZOLVE-AA study of rezpegaldesleukin (rezpeg) for severe-to-very-severe alopecia areata. Investors often re-rate clinical-stage biotech stocks quickly when longer-duration data suggest responses can deepen over time and when management signals a clearer path to late-stage (Phase 3) development.

Details:

Nektar disclosed 52-week topline results from a blinded extension (weeks 36–52) of the Phase 2b REZOLVE-AA trial evaluating rezpegaldesleukin in alopecia areata.

The company highlighted “deepening” responder rates with continued twice-monthly dosing, including additional patients achieving meaningful hair regrowth thresholds between weeks 36 and 52.

In the extension cohort, 31 patients continued treatment (27 on active drug across two dose arms and 4 on placebo), and the company noted high completion through 52 weeks.

Nektar said the safety profile with twice-monthly dosing remained consistent with previously reported results and that the findings support advancing rezpegaldesleukin into late-stage development in alopecia areata.

Sources:

Nektar Therapeutics, U.S. Securities and Exchange Commission

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NKTR Insider Trading Activity

$NKTR insiders have traded $NKTR stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $NKTR stock by insiders over the last 6 months:

JONATHAN ZALEVSKY (Chief R&D Officer) has made 0 purchases and 3 sales selling 5,204 shares for an estimated $213,877.
HOWARD W ROBIN (President & CEO) has made 0 purchases and 2 sales selling 2,630 shares for an estimated $150,674.
MARK ANDREW WILSON (Chief Legal Officer) sold 630 shares for an estimated $34,196

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive NKTR Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$NKTR Hedge Fund Activity

We have seen 97 institutional investors add shares of $NKTR stock to their portfolio, and 82 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FARALLON CAPITAL MANAGEMENT LLC removed 791,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $33,443,480
TWO SEAS CAPITAL LP added 745,185 shares (+inf%) to their portfolio in Q4 2025, for an estimated $31,506,421
PROSIGHT MANAGEMENT, LP added 554,633 shares (+inf%) to their portfolio in Q4 2025, for an estimated $23,449,883
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 541,586 shares (-58.6%) from their portfolio in Q4 2025, for an estimated $22,898,256
MORGAN STANLEY removed 362,730 shares (-39.0%) from their portfolio in Q4 2025, for an estimated $15,336,224
ARMISTICE CAPITAL, LLC added 328,000 shares (+122.4%) to their portfolio in Q4 2025, for an estimated $13,867,840
SOFINNOVA INVESTMENTS, INC. added 320,211 shares (+270.4%) to their portfolio in Q4 2025, for an estimated $13,538,521

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$NKTR Analyst Ratings

Wall Street analysts have issued reports on $NKTR in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

TD Cowen issued a "Buy" rating on 03/17/2026
BTIG issued a "Buy" rating on 01/29/2026
Citigroup issued a "Buy" rating on 11/26/2025
Jefferies issued a "Buy" rating on 11/26/2025

To track analyst ratings and price targets for $NKTR, check out Quiver Quantitative's $NKTR forecast page.

$NKTR Price Targets

Multiple analysts have issued price targets for $NKTR recently. We have seen 6 analysts offer price targets for $NKTR in the last 6 months, with a median target of $136.5.

Here are some recent targets:

Martin Fan from Wedbush set a target price of $70.0 on 03/24/2026
Samantha Semenkow from Citigroup set a target price of $123.0 on 03/16/2026
Mayank Mamtani from B. Riley Securities set a target price of $150.0 on 02/23/2026
Julian Harrison from BTIG set a target price of $151.0 on 02/10/2026
Arthur He from HC Wainwright & Co. set a target price of $165.0 on 02/10/2026
Roger Song from Jefferies set a target price of $121.0 on 11/26/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.